Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer

Radiotherapy and Oncology

Volumn 92, Issue 2, 2009, Pages 226-230

  Bjerregaard, Jon K ^a,b   Mortensen, Michael B ^a   Jensen, Helle A ^a   Fristrup, Claus ^a   Svolgaard, Birgitte ^a   Schønnemann, Katrine R ^a   Hansen, Tine P ^a   Nielsen, Morten ^a   Johansen, Jørgen ^a   Pfeiffer, Per ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Chemotherapy; Locally advanced; Neo adjuvant; Pancreatic cancer; Radiotherapy

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; BILIRUBIN; FOLINIC ACID; UFT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CLINICAL EVALUATION; COLON OBSTRUCTION; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DOSIMETRY; FATIGUE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; INTESTINE OBSTRUCTION; KAPLAN MEIER METHOD; KIDNEY INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PAIN; PALLIATIVE THERAPY; PANCREAS ADENOCARCINOMA; PATIENT SELECTION; PNEUMONIA; PNEUMOPERITONEUM; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RASH; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME; UPPER GASTROINTESTINAL BLEEDING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TEGAFUR; URACIL;

EID: 67650948376     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.04.010     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Imamura M., Doi R., Imaizumi T., et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 136 (2004) 1003-1011
3. Krzyzanowska M.K., Weeks J.C., and Earle C.C. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 21 (2003) 3409-3414
4. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25 (2007) 2212-2217
5. Bilimoria K.Y., Bentrem D.J., Ko C.Y., et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 110 (2007) 738-744
6. Cardenes H.R., Chiorean E.G., Dewitt J., Schmidt M., and Loehrer P. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 11 (2006) 612-623
7. Sultana A., Tudur Smith C., Cunningham D., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96 (2007) 1183-1190
8. Sultana A., Smith C.T., Cunningham D., Starling N., Neoptolemos J.P., and Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25 (2007) 2607-2615
9. Sultana A., Tudur Smith C., Cunningham D., Starling N., Neoptolemos J.P., and Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 99 (2008) 6-13
10. Brunner T.B., Tinkl D., Grabenbauer G.G., Meyer T., Brueckl W.M., and Sauer R. Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients. Strahlenther Onkol 182 (2006) 210-215
11. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-5.
12. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53 (2002) 146-150
13. Allendorf J.D., Lauerman M., Bill A., et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg 12 (2008) 91-100
14. Lygidakis N.J., Singh G., Bardaxoglou E., et al. Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study. Hepatogastroenterology 51 (2004) 427-433
15. Tseng J.F., Raut C.P., Lee J.E., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8 (2004) 935-949
16. Siriwardana H.P., and Siriwardena A.K. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 93 (2006) 662-673
17. Katz M.H., Pisters P.W., Evans D.B., et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206 (2008) 833-846
18. Li C.P., Chao Y., Chi K.H., et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57 (2003) 98-104
19. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299 (2008) 1019-1026
20. Childs III H.A., Spencer S.A., Raben D., Bonner J.A., Newsome J., and Robert F. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 47 (2000) 939-944
21. Vestermark L.W., Jacobsen A., Qvortrup C., et al. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta Oncol 47 (2008) 428-433
22. Douillard J.Y., Hoff P.M., Skillings J.R., et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (2002) 3605-3616
23. Pfeiffer P. High-dose radiotherapy and concurrent UFT plus l-leucovorin in locally advanced rectal cancer: a phase I trial. Acta Oncol 44 (2005) 224-229
24. Bajetta E., Di Bartolomeo M., Stani S.C., et al. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys 45 (1999) 285-289
25. Snady H., Bruckner H., Cooperman A., Paradiso J., and Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89 (2000) 314-327
26. Adhoute X., Smith D., Vendrely V., et al. Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy. Gastroenterol Clin Biol 30 (2006) 224-230
27. White R.R., Xie H.B., Gottfried M.R., et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 12 (2005) 214-221
28. Hoffman J.P., Lipsitz S., Pisansky T., Weese J.L., Solin L., and Benson A.B. III phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16 (1998) 317-323
29. Sa Cunha A., Rault A., Laurent C., et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 201 (2005) 359-365
30. Isacoff W.H., Bendetti J.K., Barstis J.J., Jazieh A.R., Macdonald J.S., and Philip P.A. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol 25 (2007) 1665-1669
31. Todd K.E., Gloor B., Lane J.S., Isacoff W.H., and Reber H.A. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 2 (1998) 159-166
32. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 (2008) 3496-3502
33. Varadhachary G.R., Wolff R.A., Crane C.H., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26 (2008) 3487-3495
34. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25 (2007) 326-331
35. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 (2008) 1592-1599
36. Loehrer Sr. P.J., Powell M.E., Cardenes H.R., et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 (Meeting Abstracts). J Clin Oncol 26 (2008) 4506
37. Farrell J.J., Elsaleh H., Garcia M., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136 (2009) 187-195